The advent of frontline immunotherapy has significantly extended survival for certain patients with metastatic non-small cell lung cancer (NSCLC). As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Jared Weiss, Prof. Aleš Ryška, and Dr. Mihaela Aldea provide privileged insights into the nuances of biomarker testing, optimal regimen selection, and management of immune-related adverse events.
Upon completion of this activity, participants should be better able to:
Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, United States
Head, Fingerland Department of Pathology
Charles University Medical Faculty
Hradec Králové University Hospital
Prague, Czech Republic
Associate Professor, Medical Oncology
Paris-Saclay University
Gustave Roussy
Villejuif, France
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
